Premium
Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio‐oedema
Author(s) -
Pressler A.,
Grosber M.,
Halle M.,
Ring J.,
Brockow K.
Publication year - 2013
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2012.04430.x
Subject(s) - omalizumab , medicine , ketotifen , dermatology , edema , chronic urticaria , angioedema , immunoglobulin e , surgery , antibody , immunology , asthma
Summary Vibratory angio‐oedema is a rare form of physical urticaria characterized by pruriginous weals and angio‐oedema at the site of exposure to vibration. Severe treatment‐resistant disease can occur, and is associated with significant disability. Therapy with omalizumab, a monoclonal IgG anti‐IgE antibody, has been shown to be successful in several types of physical urticaria. We report a patient with vibratory angio‐oedema for whom all standard treatments for urticaria, including omalizumab, failed to show a clinical benefit. Finally, ketotifen was tried, and unexpectedly reduced symptoms significantly. Ketotifen may thus represent a therapeutic option in patients with treatment‐resistant vibratory angio‐oedema.